

# Laurence D Sterns

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/3878092/publications.pdf>

Version: 2024-02-01

56  
papers

1,917  
citations

394286

19  
h-index

254106

43  
g-index

59  
all docs

59  
docs citations

59  
times ranked

2035  
citing authors

#	ARTICLE	IF	CITATIONS
1	Ventricular Tachycardia Ablation versus Escalation of Antiarrhythmic Drugs. <i>New England Journal of Medicine</i> , 2016, 375, 111-121.	13.9	616
2	A Comparison of Empiric to Physician-Tailored Programming of Implantable Cardioverter-Defibrillators. <i>Journal of the American College of Cardiology</i> , 2006, 48, 330-339.	1.2	225
3	Low inappropriate shock rates in patients with single- and dual/triple-chamber implantable cardioverter-defibrillators using a novel suite of detection algorithms: PainFree SST trial primary results. <i>Heart Rhythm</i> , 2015, 12, 926-936.	0.3	130
4	Complications Associated With Revision of Sprint Fidelis Leads. <i>Circulation</i> , 2010, 121, 2384-2387.	1.6	88
5	Canadian Cardiovascular Society/Canadian Heart Rhythm Society 2016 Implantable Cardioverter-Defibrillator Guidelines. <i>Canadian Journal of Cardiology</i> , 2017, 33, 174-188.	0.8	84
6	Outcome of the Fidelis implantable cardioverter-defibrillator lead advisory: A report from the Canadian Heart Rhythm Society Device Advisory Committee. <i>Heart Rhythm</i> , 2008, 5, 639-642.	0.3	79
7	Outcome of advisory implantable cardioverter-defibrillator replacement: One-year follow-up. <i>Heart Rhythm</i> , 2008, 5, 1675-1681.	0.3	66
8	Randomized Ablation-Based Rhythm-Control Versus Rate-Control Trial in Patients With Heart Failure and Atrial Fibrillation: Results from the RAFT-AF trial. <i>Circulation</i> , 2022, 145, 1693-1704.	1.6	54
9	Effect of a Taser shot to the chest of a patient with an implantable defibrillator. <i>Heart Rhythm</i> , 2006, 3, 339-341.	0.3	47
10	Efficacy and Safety of Same-Day Discharge for Atrial Fibrillation Ablation. <i>JACC: Clinical Electrophysiology</i> , 2020, 6, 609-619.	1.3	47
11	Inappropriate shocks in single-chamber and subcutaneous implantable cardioverter-defibrillators: a systematic review and meta-analysis. <i>Europace</i> , 2017, 19, 1973-1980.	0.7	38
12	Safety, efficacy, and performance of new discrimination algorithms to reduce inappropriate and unnecessary shocks: the PainFree SST clinical study design. <i>Europace</i> , 2011, 13, 1484-1493.	0.7	33
13	Cardiac Resynchronization Therapy Reduces Ventricular Arrhythmias in Primary but Not Secondary Prophylactic Implantable Cardioverter Defibrillator Patients. <i>Circulation: Arrhythmia and Electrophysiology</i> , 2017, 10, .	2.1	31
14	Incidence, Predictors, and Procedural Results of Upgrade to Resynchronization Therapy. <i>Circulation: Arrhythmia and Electrophysiology</i> , 2015, 8, 152-158.	2.1	29
15	Cesium chloride induced ventricular arrhythmias in dogs: three-dimensional activation patterns and their relation to the cesium dose applied. <i>Basic Research in Cardiology</i> , 2000, 95, 152-162.	2.5	27
16	Cost Effectiveness of Ventricular Tachycardia Ablation Versus Escalation of Antiarrhythmic Drug Therapy. <i>JACC: Clinical Electrophysiology</i> , 2018, 4, 660-668.	1.3	27
17	Mexiletine or catheter ablation after amiodarone failure in the VANISH trial. <i>Journal of Cardiovascular Electrophysiology</i> , 2018, 29, 603-608.	0.8	26
18	Extended detection time to reduce shocks is safe in secondary prevention patients: The secondary prevention substudy of PainFree SST. <i>Heart Rhythm</i> , 2016, 13, 1489-1496.	0.3	24

#	ARTICLE	IF	CITATIONS
19	Catheter ablation for persistent atrial fibrillation: A multicenter randomized trial of pulmonary vein isolation (PVI) versus PVI with posterior left atrial wall isolation (PWI) - The CAPLA study. American Heart Journal, 2022, 243, 210-220.	1.2	21
20	Optimum lesion set and predictors of outcome in persistent atrial fibrillation ablation: a meta-regression analysis. Europace, 2019, 21, 1176-1184.	0.7	20
21	Ablation of atrial fibrillation after the retirement age: considerations on safety and outcome. Journal of Interventional Cardiac Electrophysiology, 2010, 28, 193-197.	0.6	19
22	Effect of Baseline Antiarrhythmic Drug on Outcomes With Ablation in Ischemic Ventricular Tachycardia. Circulation: Arrhythmia and Electrophysiology, 2018, 11, e005663.	2.1	18
23	Transesophageal Echocardiography for the Prevention of Embolic Complications After Catheter Ablation for Atrial Fibrillation. Journal of Cardiovascular Electrophysiology, 2009, 20, 1217-1222.	0.8	15
24	Mortality Risk Increases With Clustered Ventricular Arrhythmias in Patients With Implantable Cardioverter-Defibrillators. JACC: Clinical Electrophysiology, 2020, 6, 327-337.	1.3	15
25	A trial design for evaluation of empiric programming of implantable cardioverter defibrillators to improve patient management. Current Controlled Trials in Cardiovascular Medicine, 2004, 5, 12.	1.5	11
26	Feedback to providers improves evidence-based implantable cardioverter-defibrillator programming and reduces shocks. Heart Rhythm, 2015, 12, 545-553.	0.3	11
27	2021 Update on Safety of Magnetic Resonance Imaging: Joint Statement From Canadian Cardiovascular Society/Canadian Society for Cardiovascular Magnetic Resonance/Canadian Heart Rhythm Society. Canadian Journal of Cardiology, 2021, 37, 835-847.	0.8	10
28	Double Transseptal Puncture for Catheter Ablation of Atrial Fibrillation: Safety of the Technique and Its Use in the Outpatient Setting. Cardiology Research and Practice, 2010, 2010, 1-5.	0.5	9
29	Management of Implantable Cardioverter Defibrillator Recipients: Care Beyond Guidelines. Canadian Journal of Cardiology, 2017, 33, 977-990.	0.8	8
30	Use of an Intracardiac Electrogram Eliminates the Need for a Surface ECG during Implantable Cardioverter-Defibrillator Follow-Up. PACE - Pacing and Clinical Electrophysiology, 2007, 30, 1432-1437.	0.5	7
31	Estimating the incidence of atrial fibrillation in single-chamber implantable cardioverter defibrillator patients. PACE - Pacing and Clinical Electrophysiology, 2018, 42, 132-138.	0.5	7
32	Outcomes of paroxysmal atrial fibrillation ablation studies are affected more by study design and patient mix than ablation technique. Journal of Cardiovascular Electrophysiology, 2018, 29, 1471-1479.	0.8	7
33	Additional antitachycardia pacing programming strategies further reduce unnecessary implantable cardioverter-defibrillator shocks. Heart Rhythm, 2020, 17, 98-105.	0.3	7
34	Remote-only monitoring for patients with cardiac implantable electronic devices: a before-and-after pilot study. CMAJ Open, 2021, 9, E53-E61.	1.1	7
35	Novel ventricular tachyarrhythmia detection enhancement detects undertreated life-threatening arrhythmias. Heart Rhythm O2, 2022, 3, 70-78.	0.6	6
36	SVT discrimination algorithms significantly reduce the rate of inappropriate therapy in the setting of modern-day delayed high-rate detection programming. Journal of Cardiovascular Electrophysiology, 2019, 30, 2877-2884.	0.8	5

#	ARTICLE	IF	CITATIONS
37	Advances in follow-up techniques for implantable defibrillators. American Heart Journal, 1994, 127, 1081-1085.	1.2	4
38	Do patients at high risk of nonsudden cardiac death benefit from prophylactic ICD therapy?. Current Opinion in Cardiology, 2012, 27, 1-7.	0.8	4
39	Canadian Registry of Implantable Electronic Device Outcomes: Longer-term follow-up of the Riata lead under advisory. Heart Rhythm, 2018, 15, 524-529.	0.3	4
40	Ventricular tachycardia characteristics and outcomes with catheter ablation vs. antiarrhythmic therapy: insights from the VANISH trial. Europace, 2022, 24, 1112-1118.	0.7	4
41	992â€“114 Atrial Recordings for the Differentiation of Ventricular and Supraventricular Tachyarrhythmias. Journal of the American College of Cardiology, 1995, 25, 317A.	1.2	3
42	QT Dispersion in 120 Electrocardiographic Leads in Patients with Structural Heart Disease. PACE - Pacing and Clinical Electrophysiology, 2002, 25, 20-31.	0.5	3
43	Atrioventricular Nodal Non Re-Entrant Tachycardia (AVNNT). Heart Lung and Circulation, 2017, 26, 524-525.	0.2	3
44	Canadian national electrophysiology ablation registry report 2011â€“2016. BMC Health Services Research, 2021, 21, 435.	0.9	3
45	944-116 Focal Activation Patterns of Cesium Chloride Induced Torsades-de Pointes Tachycardias. Journal of the American College of Cardiology, 1995, 25, 170A.	1.2	2
46	A Wide Complex Tachycardia with Changing Atrial Activation Sequence. PACE - Pacing and Clinical Electrophysiology, 2013, 36, e23-e26.	0.5	2
47	Esophageal perforation after radiofrequency ablation for atrial fibrillation. Asian Cardiovascular and Thoracic Annals, 2014, 22, 1116-1118.	0.2	2
48	Ejectable loop recorders?. Heart Rhythm, 2016, 13, 2105.	0.3	2
49	Canadian Registry of Implantable Electronic Device Outcomes: Surveillance of High-Voltage Leads. Canadian Journal of Cardiology, 2018, 34, 808-811.	0.8	2
50	Canadian Registry of Electronic Device Outcomes: remote monitoring outcomes in the Abbott battery performance alertâ€“a multicentre cohort. Europace, 2021, 23, 1319-1323.	0.7	2
51	P2-58. Heart Rhythm, 2006, 3, S157-S158.	0.3	1
52	Canadian Registry of Electronic Device Outcomes (CREDO): The Abbott ICD Premature Battery Depletion Advisory, a Multicentre Cohort Study. CJC Open, 2021, 3, 48-53.	0.7	1
53	Comparative effectiveness of ventricular tachycardia ablation vs. escalated antiarrhythmic drug therapy by location of myocardial infarction: a sub-study of the VANISH trial. Europace, 2022, 24, 948-958.	0.7	1
54	Pulmonary vein isolation is always associated with Troponin elevation. Heart Rhythm, 2005, 2, S313.	0.3	0

#	ARTICLE	IF	CITATIONS
55	P1-38. Heart Rhythm, 2006, 3, S119-S120.	0.3	0
56	Response to Letter Regarding Article, "Complications Associated With Revision of Sprint Fidelis Leads: Report From the Canadian Heart Rhythm Society Device Advisory Committee." Circulation, 2011, 123, .	1.6	0